 HOUSTON, March 12, 2021 GLOBE NEWSWIRE -- Aravive, Inc. Nasdaq:ARAV, a clinical-stage oncology company developing transformative therapeutics, today announced that updated data from its Phase 1b trial evaluating AVB-500 in platinum resistant ovarian cancer PROC will be presented at the 2021 Society of Gynecologic Oncology Annual Meeting on Womens Cancer. Additionally, a trial in progress poster will be presented on an open label Phase 12 investigator-sponsored trial of AVB-500 in combination with durvalumab in patients with platinum resistant, recurrent epithelial ovarian cancer. The meeting is being held virtually on March 19-25, 2021. 